CLINICAL TRIALS PROFILE FOR FLUMAZENIL

All Clinical Trials for flumazenil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000246 ↗	Rapid Benzodiazepine Detoxification Using Flumazenil - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1993-01-01	The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.
NCT00000246 ↗	Rapid Benzodiazepine Detoxification Using Flumazenil - 1	Completed	Yale University	Phase 2	1993-01-01	The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.
NCT00176670 ↗	A GameBoy as a Distraction Before Surgery in Children	Completed	University of Medicine and Dentistry of New Jersey	Phase 2	2004-01-01	Preoperative anxiety is characterized by subjective feelings of tension, apprehension, nervousness and worry. In children, preoperative anxiety is reported to result in postoperative negative psychological effects, including nightmares, separation anxiety, eating problems and increased fear of doctors. Anxiety in children can be expressed in many forms. Many children look scared, become agitated, breathe deeply, tremble, and stop talking or playing and start to cry. They may unexpectedly urinate or may actively attempt to escape from the medical personnel. These reactions reflect the child's fear of separation from the parents, as well as loss of control, unfamiliar routines, instruments and hospital procedures [1]. Previous studies have assessed anxiety in children during the preoperative period and the effects of premedication and parental presence during induction of anesthesia (PPIA) [2]. Midazolam has been proven to reduce preoperative anxiety in children [3]. Side effects related to oral midazolam administered to healthy children are minimal and the drug can be reversed with flumazenil but post operative recovery may be delayed in those children undergoing a short surgical procedure. It is the experience of the investigator that there are some children who have such low levels of anxiety they do not require any intervention Distraction may be particularly helpful in children ages 6-12 as these children may not receive preoperative medication due to their curiosity about the environment. Previous studies regarding distraction therapy have focused on the parent either blowing bubbles or reading to a child [4]. Studies where the child is actively engaged in a distraction activity have not been documented. The purpose of this investigation is to determine whether in the presence of a parent an interactive distraction intervention, i.e. Game Boy which is a hand held video game, is as effective as preoperative Midazolam in reducing preoperative anxiety. This study may help in the search for a low cost and easy to implement method of reducing anxiety for children undergoing surgery.
NCT00262639 ↗	Prometa Protocol for Alcohol Dependence	Completed	Medical University of South Carolina	Phase 2/Phase 3	2005-12-01	This is a placebo controlled trial (some people receive active and some people receive inactive medication) to evaluate the effectiveness of a new protocol to treat alcohol dependence. Two main medications (plus ancillary non-placebo controlled medications) and their placebos (inactive drugs) will be utilized to treat both alcohol withdrawal, promote abstinence, and reduce drinking over approximately a six-week treatment period. All participants will meet criteria for Alcohol Dependence and be drinking heavily up until 72 hours prior to receiving the first study drug. They will be injected one drug (flumazenil or placebo) over a two day period and receive the second one (gabapentin or placebo) by mouth for 39 days. The main hypothesis is that this protocol will reduce early alcohol withdrawal symptoms and will reduce relapse to drinking and promote abstinence compared to the placebo (inactive) drug group. Secondary outcomes that will be evaluated include reduction in craving, improvement in sleep, brain activity and mood.
NCT00570388 ↗	Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence	Unknown status	Institute of Addiction Medicine	N/A	2007-03-01	This study will test the safety and efficacy of the PROMETA® Treatment Protocol (which includes the benzodiazepine antagonist flumazenil) in reversing the neurocognitive impairment and this in turn will lead to improved ability to resist alcohol related cues and enhance involvement in psychosocial treatment.
NCT00681720 ↗	Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325	Completed	AstraZeneca	Phase 1	2008-02-01	The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.
NCT00681746 ↗	Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280	Completed	AstraZeneca	Phase 1	2008-02-01	The study is carried out in order to determine the relationship between the dose of AZD6280 and the blood concentration of AZD6280, and to investigate to which extent AZD6280 binds to GABAA receptors

Clinical Trial Conditions for flumazenil

Condition Name

Condition Name for flumazenil
Intervention	Trials
Remimazolam	10
Anesthesia, General	3
Emergence Agitation	3
Healthy	3

Condition MeSH

Condition MeSH for flumazenil
Intervention	Trials
Emergence Delirium	6
Delirium	4
Alcoholism	3
Atrial Fibrillation	2

Clinical Trial Locations for flumazenil

Trials by Country

Trials by Country for flumazenil
Location	Trials
United States	18
Korea, Republic of	15
China	15
South Korea	4
Israel	2

Trials by US State

Trials by US State for flumazenil
Location	Trials
Connecticut	3
Michigan	2
California	2
Pennsylvania	2
South Carolina	2

Clinical Trial Progress for flumazenil

Clinical Trial Phase

Clinical Trial Phase for flumazenil
Clinical Trial Phase	Trials
PHASE4	5
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for flumazenil
Clinical Trial Phase	Trials
COMPLETED	22
Recruiting	14
Not yet recruiting	12

Clinical Trial Sponsors for flumazenil

Sponsor Name

Sponsor Name for flumazenil
Sponsor	Trials
Seoul National University Hospital	5
Second Affiliated Hospital of Nanchang University	4
Asan Medical Center	3

Sponsor Type

Sponsor Type for flumazenil
Sponsor	Trials
Other	69
Industry	7
NIH	5

Last updated: April 25, 2026

Flumazenil: Clinical Trials Update, Market Analysis, and Projections

Flumazenil is a benzodiazepine receptor antagonist used to reverse benzodiazepine-induced sedation and to treat selected cases of benzodiazepine overdose. Commercially, it remains a niche but durable product with use concentrated in acute care and peri-procedural settings. Patent and regulatory history is dominated by older originator filings and subsequent generics, leaving limited headroom for new entrants unless they pursue new formulations, delivery systems, or additional labeled indications.

---

What is the current clinical-trials activity for flumazenil?

Public clinical-trials activity for flumazenil in recent years is sparse relative to major CNS assets and is largely composed of academic or investigator-led studies, small cohorts, or formulation and comparative effectiveness work. Trial focus typically centers on:

• Reversal efficacy and time-to-effect in peri-procedural sedation contexts
• Management strategies in suspected benzodiazepine toxidromes
• Administration route comparisons (where studied)
• Safety and dosing parameters in specific patient subpopulations

Clinical-trials intelligence snapshot (registry-based):

• ClinicalTrials.gov is the primary source for prospective, identifiable interventional trials and provides the most direct view of new start-ups, status changes, and results publication. Search and status review show a recurring presence of small, older, or recruiting/completed studies rather than a sustained, large global late-stage program (ClinicalTrials.gov). [1]

Key takeaway on pipeline dynamics:

• The clinical pipeline around flumazenil is not driven by large-scale phase 3 expansion. Instead, activity clusters around incremental questions (dose, timing, comparative reversal strategy, and narrow indication refinement) and does not indicate broad phase 3 development momentum.

---

Where is flumazenil marketed and how is it used in practice?

Flumazenil is administered intravenously in acute reversal scenarios and for peri-procedural benzodiazepine reversal. The market use pattern is driven by:

• Hospital emergency and inpatient settings for suspected benzodiazepine intoxication
• Procedural sedation workflows (endoscopy, imaging, minor procedures) where benzodiazepine reversal capability is part of standard safety protocols in many systems
• Operating room and post-anesthesia care unit pathways that depend on sedation agents used

Regulatory and labeling anchor points:

• Flumazenil is an established reversal agent for benzodiazepines; labeling typically specifies dosing, repeat dosing intervals, and patient monitoring requirements (FDA labels). [2]

---

How does flumazenil compete: brand vs. generics vs. alternative reversal agents?

Brand and generic landscape

Flumazenil faces strong competitive pressure from generic versions across major markets. Pricing and contracting typically track generic availability and tender mechanics rather than premium differentiation.

Therapeutic competition

Competition is not only within the benzodiazepine reversal space (where flumazenil is the specific antagonist). Key practical substitutes include:

• Non-pharmacologic supportive care and monitoring approaches in overdose management
• Alternative sedation reversal strategies in procedural settings depending on the sedation regimen used
• For certain settings, workflows may be optimized around avoiding benzodiazepines where appropriate rather than reversing them

This competitive structure keeps flumazenil’s value proposition tied to availability, dosing convenience, and hospital formulary acceptance.

---

What does the market look like today?

Demand drivers

• Continued use of benzodiazepines in procedural sedation and anxiolysis
• Persistent incidence of benzodiazepine overdose presentations (including iatrogenic and accidental exposure)
• Hospital protocols that maintain reversal capability as part of sedation safety

Market constraints

• Niche use relative to blockbuster CNS drugs
• Strong generic penetration limiting pricing power
• Clinical practice variability by institution and country (protocols, sedation agent selection, and monitoring standards)

Market size and growth

A reliable, current market value estimate requires consolidated commercial datasets (IMS, IQVIA, company-reported revenue, or payer claims) which are not provided in the available public sources in this brief. The forecast below therefore focuses on directionality and structural drivers, not a single-point dollar market sizing.

---

How will the market evolve: drivers, headwinds, and likely trajectory?

Near-term (12-36 months)

• Stability bias: Demand remains anchored to ongoing benzodiazepine use and acute-care protocols.
• Pricing pressure persists: Generic competition keeps net price low and reduces upside from brand-led growth.
• Conversion depends on formulary and protocol updates: Hospitals update peri-procedural sedation workflows slowly; changes typically propagate through purchasing cycles.

Mid-term (3-7 years)

• Incremental innovation window: Market share shifts can occur if a company launches a differentiated formulation, lower-volume dosing, ready-to-use presentations, or improved stability that reduces handling burdens for ER and procedural units.
• No broad late-stage expansion signal: Without a meaningful new labeled indication or large phase 3 program, growth is unlikely to come from clinical “value leaps.”

Long-term (7+ years)

• Sustained niche equilibrium: Unless a major new indication is established or clinical guidelines shift materially toward higher reversal utilization, the market stays limited in scale.
• Patent strategy constraints: With older originator periods, long exclusivity for flumazenil itself is largely exhausted; future growth depends on product-level differentiation rather than molecule-level protection.

---

What do the sources say about clinical and regulatory context?

• ClinicalTrials.gov provides ongoing visibility into interventional studies, including status changes and results reporting for flumazenil (ClinicalTrials.gov). [1]
• FDA labeling documents define approved indications, dosing, and safety monitoring considerations, framing the practical boundaries that shape utilization in hospitals (FDA labels). [2]

---

Clinical evidence and dosing realities that shape adoption

Flumazenil’s adoption is less about marginal efficacy and more about execution quality in acute settings:

• Time-to-reversal and the ability to titrate remain key workflow variables
• Repeat dosing protocols and patient monitoring requirements limit use in settings that cannot safely monitor respiratory function
• Contraindication and caution frameworks in mixed overdose or seizure risk contexts impact prescribing decisions and emergency physician comfort

These elements are reflected in labeling language and in how hospitals implement sedation and overdose protocols (FDA labels). [2]

---

Market projection: quantified outlook model (directional, scenario-based)

Because a precise current market base is not provided in the available sources here, the projection uses scenario logic to translate structural variables into likely market behavior.

Scenario framework

1. Base case (most likely): Stable demand, modest volume fluctuation, continued low pricing from generics
2. Downside case: Further consolidation of hospital formularies toward narrower emergency and sedation drug lists, reduced procedural benzodiazepine use, or substitution by alternative strategies
3. Upside case: Guideline-driven increased reversal utilization in procedural sedation pathways and adoption of operationally improved formulations

Expected trajectory

• Volume: Flat-to-slightly up in acute and peri-procedural settings due to ongoing benzodiazepine use
• Price: Flat-to-down due to generics and procurement leverage
• Value: Flat to low-growth unless a differentiated product meaningfully improves hospital handling or demonstrably reduces monitoring burden

This structural outlook is consistent with a mature, off-patent molecule with limited pipeline expansion.

---

Key business implications for R&D and investment

• Molecule-level exclusivity is not the growth lever. Future value creation must come from product differentiation (formulation, presentation, delivery, or localized regulatory advantages) rather than a new mechanism of action.
• Clinical program design should target workflow metrics. For flumazenil, “time-to-reversal” and practical titration safety outcomes drive adoption more than broad symptom endpoints.
• Regulatory strategy should align with existing labeling logic. New trials should connect directly to approved use boundaries to minimize integration friction into hospital protocols.

---

Key Takeaways

• Flumazenil is a mature benzodiazepine reversal agent with limited clinical pipeline momentum relative to major CNS drugs; trial activity appears mostly incremental and registry-driven.
• Market dynamics are dominated by generics and hospital procurement, keeping pricing constrained and value growth modest.
• Sustainable upside depends on product-level differentiation and guideline or protocol shifts that increase or optimize flumazenil utilization.
• Without new labeled indications backed by large phase 3 evidence, projections center on stable volume and low-to-flat value growth.

---

FAQs

1. Is flumazenil still actively studied in clinical trials?
   Yes, registry activity exists but appears limited in scale and largely focused on reversal-related questions rather than major new clinical programs (ClinicalTrials.gov). [1]

2. What is flumazenil’s core approved use?
   It is used to reverse benzodiazepine effects, with dosing and monitoring guidance defined in FDA labeling (FDA labels). [2]

3. Why does market growth look constrained for flumazenil?
   Off-patent competition from generics and narrow use tied to benzodiazepine reversal workflows limit pricing power and scale.

4. What types of innovations could move adoption?
   Operationally improved formulations or presentations that reduce handling burden and support safe titration in ER and procedural settings.

5. What will most influence future market performance?
   Hospital sedation and overdose protocols, procurement cycles, and whether any differentiated product meaningfully changes workflow adoption.

---

References

[1] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. (n.d.). FDA Labeling (Flumazenil products). https://www.accessdata.fda.gov/